Therapy News and Research

RSS

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.

28 Aug 2012

Diaverum plans to increase peritoneal dialysis use among patients with ESRD

Diaverum, one of the world's leading renal care providers, is planning to give more patients the possibility to be treated with peritoneal dialysis to increase their quality of life.

27 Aug 2012

Insulin glargine retards progression of atherosclerosis in high-risk people

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

27 Aug 2012

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Renal denervation leads to better outcomes than standard drug treatment in patients with advanced heart failure, according to research presented at ESC Congress 2012. The results of the Olomouc I pilot study were presented by Dr Miloš Táborský from the University Hospital Olomouc.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

Spironolactone should be considered as a treatment option in hypertensive patients with DHF

Mineralocorticoid receptor antagonists should be considered as a treatment option in hypertensive patients with diastolic heart failure, said Professor Burkert Pieske presenting results today of the Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) study at ESC Congress 2012.

27 Aug 2012

Baylor Plano first hospital to merge MEM software and Epoch platform for atrial fibrillation therapy

Baylor Plano became the first hospital in the world on Friday to merge two highly advanced technologies for atrial fibrillation therapy.

27 Aug 2012

IABP does not improve blood pressure symptoms in patients with cardiogenic shock

A balloon pump inserted in the aorta is currently the most widely used support device in the treatment of cardiogenic shock and, since its introduction in 1968, has been used in several million people.

27 Aug 2012

Renal denervation safe and effective in patients with treatment resistant hypertension

Renal denervation leads to significant and sustained blood pressure reduction for up to 18 months in patients with treatment resistant hypertension, according to research presented at ESC Congress 2012.

27 Aug 2012

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced that the first patient has been enrolled in an open-label phase III study to investigate the efficacy, safety, and pharmacokinetics of the sustained release triptorelin pamoate 22.5 mg 6-month-formulation in children with central precocious puberty (CPP), a rare disease.

27 Aug 2012

Obesity at diagnosis of breast cancer associated with increased risk of recurrence

Extra pounds-even within the overweight but not obese range-are linked to a higher risk of recurrence of the most common type of breast cancer despite optimal cancer treatment, according to a new study published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

27 Aug 2012

XJB-5-131 prevents secondary damage of severe traumatic brain injury

Treatment with an agent that blocks the oxidation of an important component of the mitochondrial membrane prevented the secondary damage of severe traumatic brain injury and preserved function that would otherwise have been impaired, according to a research team from the University of Pittsburgh School of Medicine, Graduate School of Public Health and Department of Chemistry in a report published online today in Nature Neuroscience.

27 Aug 2012

Study confirms electrical storm as potent risk factor for death and impaired quality of life

Electrical storm (ES) is a potent risk factor for mortality and morbidity, according to research presented today at the ESC Congress 2012 by Dr Federico Guerra from Italy. Data was also presented on which patients are prone to developing ES and how effective current treatments are.

27 Aug 2012

Study: Lower use of drug eluting stents in women treated with PCI than men

Drug eluting stents (DES) are used less often in women treated with percutaneous coronary intervention (PCI) for coronary artery disease than men treated with PCI for the same condition, according to research presented today at the ESC Congress 2012.

27 Aug 2012

Female sex associated with increased risk of stroke for AF patients aged ≥75 years

Female gender increases the risk of stroke in patients with atrial fibrillation (AF) aged >75 years by 20%, according to a study presented today at the ESC Congress 2012. The findings were presented by Anders Mikkelsen, from Denmark.

27 Aug 2012

Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, today announced that Roche has reported that updated results from its EMILIA Phase III trial show that patients treated with trastuzumab emtansine had a significant improvement in OS compared to those randomized to standard-of-care therapy.

27 Aug 2012

Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death

The first trial to study patients with acute coronary syndrome who do not undergo coronary stenting or bypass surgery found no significant difference between two anti-clotting drugs - prasugrel and clopidogrel - in preventing the first occurrence of death, heart attack or stroke, according to Duke University Medical Center cardiologists.

27 Aug 2012

Patients tend to have worse outcomes when GBM appears in more than one location

When aggressive, malignant tumors appear in more than one location in the brain, patient survival tends to be significantly shorter than when the disease starts as a single tumor, even though patients in both groups undergo virtually identical treatments, according to research at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Research Institute.

27 Aug 2012

SUMO1 protein may treat and/or prevent heart failure

A promising new drug target for the treatment and prevention of heart failure has been discovered by researchers at Mount Sinai School of Medicine in New York, NY, US. The study was presented at the ESC Congress 2012 by principal investigator Professor Roger J. Hajjar, MD.

26 Aug 2012

Therapy News and Research

Gilead Sciences receives FDA approval for Stribild to treat HIV-1 infection

Diaverum plans to increase peritoneal dialysis use among patients with ESRD

Insulin glargine retards progression of atherosclerosis in high-risk people

Renal denervation leads to better outcomes than standard drug treatment in patients with AHF

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Spironolactone should be considered as a treatment option in hypertensive patients with DHF

Baylor Plano first hospital to merge MEM software and Epoch platform for atrial fibrillation therapy

IABP does not improve blood pressure symptoms in patients with cardiogenic shock

Renal denervation safe and effective in patients with treatment resistant hypertension

Debiopharm initiates enrollment in triptorelin phase III study for central precocious puberty

Obesity at diagnosis of breast cancer associated with increased risk of recurrence

XJB-5-131 prevents secondary damage of severe traumatic brain injury

Study confirms electrical storm as potent risk factor for death and impaired quality of life

Study: Lower use of drug eluting stents in women treated with PCI than men

Female sex associated with increased risk of stroke for AF patients aged ≥75 years

Results from Roche's trastuzumab emtansine Phase III trial on HER2-positive breast cancer

Prasugrel as safe as clopidogrel in preventing heart attack, stroke and death

Patients tend to have worse outcomes when GBM appears in more than one location

SUMO1 protein may treat and/or prevent heart failure

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News